Clinical Trial Update: Anlotinib-based Combination Therapy in Patients with Hormone Receptor-positive（HR+） Metastatic Breast Cancer(MBC) .

View source ↗

Summary

A recruiting clinical trial evaluating anlotinib-based combination therapy for hormone receptor-positive metastatic breast cancer, sponsored by Hunan Cancer Hos…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Breast Cancer
• Hormone Receptor-positive Breast Cancer

Drugs mentioned

• Anlotinib (anlotinib)

Snippet

Sponsor: Hunan Cancer Hospital | Conditions: HR+ Breast Cancer | Status: RECRUITING